Interestingly, in preconditioning studies in bothhuman breast and melanoma tumor cell models, anti-VEGF antibodies B20 and G6.31 yielded improvedoverall survival outcome compared to sunitinib monotherapy, but these were not significant. The gene discussed is VEGFA; the disease is neoplasm.